One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In September 2016, the U.S. Food and Drug Administration approved the Medtronic 670G “hybrid” closed-loop system. In Auto Mode, this system automatically controls basal insulin delivery based on continuous glucose monitoring data but requires users to enter carbohydrates and blood glucose for boluses. To track real-world experience with this first commercial closed-loop device, we prospectively followed pediatric and adult patients starting the 670G system. RESEARCH DESIGN AND METHODS: This was a 1-year prospective observational study of patients with type 1 diabetes starting the 670G system between May 2017 and May 2018 in clinic. RESULTS: Of the total of 84 patients who received 670G and consented, 5 never returned for follow-up, with 79 (aged 9–61 years) providing data at 1 week and 3, 6, 9, and/or 12 months after Auto Mode initiation. For the 86% (68 out of 79) with 1-week data, 99% (67 out of 68) successfully started. By 3 months, at least 28% (22 out of 79) had stopped using Auto Mode; at 6 months, 34% (27 out of 79); at 9 months, 35% (28 out of 79); and by 12 months, 33% (26 out of 79). The primary reason for continuing Auto Mode was desire for increased time in range. Reasons for discontinuation included sensor issues in 62% (16 out of 26), problems obtaining supplies in 12% (3 out of 26), hypoglycemia fear in 12% (3 out of 26), multiple daily injection preference in 8% (2 out of 26), and sports in 8% (2 out of 26). At all visits, there was a significant correlation between hemoglobin A1c (HbA1c) and Auto Mode utilization. CONCLUSIONS: While Auto Mode utilization correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure use of Auto Mode. Alarms and sensor calibration are a major patient concern, which future technology should alleviate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [210]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · cited 7×
“The REDCap platform services are made possible by the Stanford University School of Medicine Research Office.”
MethodInfluential(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 2×
“Middle Eastern 3 (4) 0 (0) 3 (6) Native American 1 (1) 1 (4) 0 (0)”
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 3×
“Prior insulin delivery systems Animas 13 (9) 3 (8) 10 (10) Medtronic, older 62 (45) 19 (49) 43 (44) Medtronic 630G 37 (27) 13 (33) 24 (24) Omnipod 5 (4) 1 (3) 4 (4) Roche 1 (1) 0 (0) 1 (1) Tandem 4 (3) 0 (0) 4 (4) Multiple daily injections 4 (3) 1 (3) 3 (3) Other 11 (8) 2 (5) 9 (9)”
Self-citationTauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationSafety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Forlenza, G. P., Pinhas-Hamiel, O., Liljenquist, D. R., Shulman, D. I., Bailey, T. S., Bode, B. W., Wood, M. A., Buckingham, B. A., Kaiserman, K. B., Shin, J., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0264 · Cited by 182
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Abraham, M. B., Nicholas, J. A., Smith, G. J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., & on behalf of the PLGM Study Group (2018) · Diabetes Care · doi:10.2337/dc17-1604 · Cited by 142
Cited by
Items 101–200 of 218
Roberts, A., Fried, L., Dart, J., de Bock, M. I., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., KEECH, A. C., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14907 · Cited by 21
Fox, D. S., Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L., Thankamony, A., Campbell, F., Wadwa, R. P., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241231950 · Cited by 18
Self-citationWho Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England
Farrington, C., Hovorka, R., & Murphy, H. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0380 · Cited by 18
Diabetology 4.0: Scoping Review of Novel Insights and Possibilities Offered by Digitalization
Eberle, C., Stichling, S., & Löhnert, M. (2021) · Journal of Medical Internet Research · doi:10.2196/23475 · Cited by 21
“Nevertheless, hybrid closed-loop systems have shown improved HbA 1c levels and time in range and decreased time spent in hypo-and hyperglycemias [55,57,58].”
Felix dies natalis, insulin… ceterum autem censeo “beta is better”
Piemonti, L. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01737-3 · Cited by 18
Horowitz, M., Kaye, W. A., Pepper, G. M., Reynolds, K. E., Patel, S., Knudson, K. C., Kale, G. K., Gutiérrez, M. E. H., Cotto, L., & Horowitz, B. S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108876 · Cited by 17
Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation
Wong, J. J., Suttiratana, S. C., Lal, R., Lum, J. W., Lanning, M. S., Dunlap, A., Arbiter, B., Hanes, S. J., Bailey, R. J., Hood, K. K., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0362 · Cited by 17
“2,10 Furthermore, data on elapsed time from discontinuation and self-report of discontinuation as well as duration of Loop use before discontinuation were not available.”
Self-citationOutcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial
Ekhlaspour, L., Raghinaru, D., Forlenza, G. P., ISGANAITIS, E. M., Kudva, Y. C., Lam, D. W.-H., Levister, C. M., O’Malley, G., Church, M. M., Lum, J. W., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221089361 · Cited by 17
Self-citationUser Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics
Chen, N. S., Boughton, C. K., Hartnell, S., Fuchs, J., Allen, J. M., Wilinska, M. E., Thankamony, A., de Beaufort, C. E., Campbell, F., Fröhlich-Reiterer, E. E., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2762 · Cited by 21
Efficacy of advanced hybrid closed loop systems for the management of type 1 diabetes in children
Ferrito, L., Passanisi, S., Bonfanti, R., Cherubini, V., Minuto, N., Schiaffini, R., & Scaramuzza, A. E. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06531-9 · Cited by 22
Mameli, C., Smylie, G. M., Galati, A., Rapone, B., Cardona‐Hernandez, R., Zuccotti, G., & Delvecchio, M. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04833-4 · Cited by 16
Malone, S. K., MATUS, A. M., Flatt, A. J., Peleckis, A. J., Grunin, L., Yu, G., Jang, S., Weimer, J. E., Lee, I., Rickels, M. R., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231182406 · Cited by 15
Folk, S. Y. L., Zappe, J., Wyne, K. L., & Dungan, K. M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241234948 · Cited by 15
“13 While there are studies that have examined the performance of HCL pumps in real-world settings, 13-15 few data compare multiple HCL systems.”
Augmented intelligence in pediatric anesthesia and pediatric critical care
Görges, M., & Ansermino, J. M. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000845 · Cited by 15
Lewis, D. M., & Hussain, S. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01299-9 · Cited by 18
“One of the frustrations cited with one of the earliest commercial AID systems was insufficient time spent in the automated insulin delivery mode [41, 44].”
BackgroundJu, Z., Piarulli, A., Bielick, L., Marschall, S., Brouillard, E., & Steenkamp, D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0334 · Cited by 15
Automated Insulin Delivery in Real Life (AID-IRL): Real-World User Perspectives on Commercial AID
Lewis, D. M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820957360 · Cited by 15
Biester, T., Bratina, N., Lange, K., Biester, S., Remus, K., Thomas, A., Danne, T., & Kordonouri, O. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1079-4577 · Cited by 14
Mise en place de l’insulinothérapie automatisée en boucle fermée : position d’experts français
Franc, S., Schaepelynck, P., Tubiana‐Rufi, N., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(20)30003-1 · Cited by 24
Youth and parent preferences for an ideal AP system: It is all about reducing burden
COMMISSARIAT, P. V., Roethke, L., Finnegan, J., Guo, Z., Volkening, L. K., Butler, D. A., Dassau, E., WEINZIMER, S. A., & Laffel, L. M. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13252 · Cited by 14
Standardized Hybrid Closed-Loop System Reporting
Shah, V. N., & Garg, S. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0622 · Cited by 14
Donaldson, L. E., Fourlanos, S., Vogrin, S., MacIsaac, R. J., Colman, P. G., & McAuley, S. A. (2023) · Internal Medicine Journal · doi:10.1111/imj.16143 · Cited by 13
Kubilay, E., Trawley, S. L., Ward, G. M., Fourlanos, S., Colman, P. G., & McAuley, S. A. (2023) · Diabetic Medicine · doi:10.1111/dme.15264 · Cited by 13
“5,6 Messer et al. found a smaller attrition rate with 3.5% of youth discontinuing Tandem t:slim Control-IQ technology use over a 6-month period.”
BackgroundInfluentialGera, S., Iyer, J., Meighan, S. S., March, C. A., & Marks, B. E. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.004 · Cited by 13
Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
The role of technology in the care of diabetes mellitus in pregnancy: an expert review
Thayer, S. M., Williams, K. J., & Lawlor, M. L. (2023) · AJOG Global Reports · doi:10.1016/j.xagr.2023.100245 · Cited by 13
Schöttler, H., Auzanneau, M., Best, F., Braune, K., Freff, M., Heidtmann, B., Jung, R., Karges, B., Klee, D., Müller, A., et al. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1259-1190 · Cited by 15
“Einstellungen der Nutzer/-innen und auch Betreuungspersonen gegenüber technischen Hilfsmitteln, psychologische und technische Aspekte spielen in der Akzeptanz dieser Hilfsmittel eine große Rolle [46, 51, 52].”
BackgroundAdjunctive Therapies to Optimize Closed-loop Glucose Control
Srinivasan, S., Ekhlaspour, L., & Cengiz, E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211032701 · Cited by 14
Automated insulin dosing systems: Advances after a century of insulin
Thabit, H., Lal, R., & Leelarathna, L. (2021) · Diabetic Medicine · doi:10.1111/dme.14695 · Cited by 14
Self-citationAdvances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience
Halim, B., Abraham, M. B., Manos, G., Arrieta, A., Dai, Z., Vogrin, S., Lu, J., MacIsaac, R. J., Ekinci, E. I., Davis, E. A., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0348 · Cited by 12
Sehgal, S., de Bock, M. I., Jones, S., Frewen, C. M., & Wheeler, B. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214975 · Cited by 12
Forlenza, G. P., Vigers, T., Berget, C., Messer, L. H., Lal, R., Basina, M., Maahs, D. M., Hood, K. K., Buckingham, B. A., Wilson, D. M., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0326 · Cited by 14
Self-citationClosed-loop therapy: recent advancements and potential predictors of glycemic outcomes
Royston, C., Hovorka, R., & Boughton, C. K. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2492363 · Cited by 12
“Studies have shown a strong positive correlation between time spent in ‘auto-mode’ and glycemic outcomes when using the Medtronic 670 G closed-loop system and prototypes of the Cambridge closed-loop system; a higher time in auto-mode was associated with increased TIR and lower HbA1c [75,76].”
Grant, A. D., Lewis, D. M., & Kriegsfeld, L. J. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821994825 · Cited by 12
Akiyama, T., Yamakawa, T., Orime, K., Ichikawa, M., Harada, M., Netsu, T., Akamatsu, R., Nakamura, K., Shinoda, S., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14103 · Cited by 13
“These were the possible reasons reported for HCL system discontinuation 21 .”
BackgroundNally, L. M., Wagner, J. A., Sherr, J. L., TICHY, E. M., Weyman, K., Ginley, M. K., Zajac, K., Desousa, M., Shabanova, V., Petry, N. M., et al. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.017 · Cited by 11
Artificial Pancreas Technology Offers Hope for Childhood Diabetes
Schoelwer, M. J., & DeBoer, M. D. (2021) · Current Nutrition Reports · doi:10.1007/s13668-020-00347-9 · Cited by 11
“Age 7–13 years Lal et al. (2019) [56] Medtronic 670G Observational N = 79 12 months Auto mode use was associated with lower HbA1c; however, 33% of 670G users discontinued use by 12 months.”
MethodSimulation-driven optimization of insulin therapy profiles in a commercial hybrid closed-loop system
C., J. L. D., Villa-Tamayo, M. F., Moscoso-Vásquez, M., & Colmegna, P. H. (2023) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2023.107830 · Cited by 12
An Analysis of 2019 FDA Adverse Events for Two Insulin Pumps and Two Continuous Glucose Monitors
Krouwer, J. S. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820951872 · Cited by 10
Pemberton, J. S., Collins, L., Drummond, L., Dias, R. P., Krone, R. E., Kershaw, M., & Uday, S. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004045 · Cited by 8
Marigliano, M., Mozzillo, E., Mancioppi, V., Candia, F. D., Rosanio, F. M., Antonelli, A., Nichelatti, I., Maffeis, C., Tumini, S., & Franceschi, R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071031 · Cited by 10
“To date, discontinuation of AID devices has been estimated at up to 30% in youth, and they discontinue most likely within the first 1–3 months of use [43,44].”
BackgroundDecision Support Systems and Closed‐Loop
Nimri, R., Phillip, M., & Kovatchev, B. P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2504 · Cited by 9
Quirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.10.005 · Cited by 11
Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor
Nally, L. M., Sherr, J. L., Garg, S. K., Marks, B. E., Laffel, L. M., Pihoker, C., Accacha, S. D., Thrasher, J. R., Abuzzahab, M. J., Reed, J. H. C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251368928 · Cited by 9
Self-citationYuan, C. Y., Kong, Y. W., Amoore, T., Brown, K., Grosman, B., Jenkins, A. J., Jones, H., Kurtz, N., Lee, M. H., MacIsaac, R. J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2217 · Cited by 8
Quirós, C., Alonso-Carril, N., Rodriguez-Rodríguez, S., Barahona, M. J., Orois, A., Simó-Servat, A., Ramos, M., & Perea, V. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.10.003 · Cited by 8
Giza, S., Kotanidou, E. P., Tsinopoulou, V. R., Poukoulidou, T., Ntouma, S., & Galli-Tsinopoulou, A. (2025) · Children · doi:10.3390/children12121668 · Cited by 7
“Studies recorded the impact of alarm fatigue among patients [18,29,31,33,34,36,43– 45,47 ,49 ,53 , 55 ], their parents [22 ,27 ,32,35,38,42,46, The main reasons responsible for alarm fatigue concerned either everyday life [22,25,29,31,33,34,37,39,41,43,45,46,49,51,52] or sleep [18,25,27,29,31–38,…”
Exposure to Closed Loop Barriers Using Virtual Reality
Lanning, M. S., Shen, J., Wasser, D., Riddle, R. S., Agustin, B., Hood, K. K., & Naranjo, D. M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820902771 · Cited by 7
“12 In 15-18 However, in order for any CL systems to be successful long term, adults and youth alike need to invest in using them and their component parts.”
BackgroundSelf-citationPROIETTI, A. E., Raggio, M., Paz, M., Rubín, G., Kabakian, M. L., Saleme, A., & Grosembacher, L. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0248 · Cited by 7
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
Efficacy of Control-IQ Technology in a General Endocrine Clinic
Usoh, C. O., Price, C. E., Johnson, C. P., Speiser, J. L., & Aloi, J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.010 · Cited by 8
Schrills, T., Gruner, M., Peuscher, H., & Franke, T. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-35748-0_23 · Cited by 7
Schütz, A. K., Rami-Merhar, B. M., Schütz-Fuhrmann, I., Blauensteiner, N., Baumann, P. M., Pöttler, T., & Mader, J. K. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241230106 · Cited by 6
“40 The OS-AID users can define individual target ranges and no calibrations are needed, and thus, are more flexible compared with commercially available systems, 27 which might be one of the various reasons for better glycemic control in OS-AID users.”
Diabetes mellitus Typ 1 – Update
Kordonouri, O., & Kerner, W. (2021) · Der Internist · doi:10.1007/s00108-021-01009-w · Cited by 6
Delvecchio, M., Galati, A., Maffeis, C., Passanisi, S., Bonfanti, R., Franceschi, R., Tornese, G., Calzi, E., Zanfardino, A., Bracciolini, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14934 · Cited by 6
Suboptimally Controlled Diabetes in Pregnancy: A Review to Guide Antepartum and Delivery Management
Cate, J. J. M., Bloom, E. A., Chu, A., Bauer, S., Kuller, J. A., & Dotters-Katz, S. K. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001270 · Cited by 7
Molfetta, S. D., Rossi, A., Gesuita, R., Faragalli, A., Cutruzzolà, A., Irace, C., Minuto, N., Pitocco, D., Cardella, F., Arnaldi, C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02381-3 · Cited by 7
“…HCL and AHCL users were pooled together, however there is evidence in the literature that users’ acceptance is increased with AHCL as compared with earlier systems, maybe due to frequent alarms and need for calibration by fingerstick glu - cose to maintain the Auto-Mode with the latters [23, 24].”
Santos, T. J. D., Rodrigues, T. D. C., Puñales, M. K., Arrais, R. F., & Kopacek, C. (2021) · Current Pediatrics Reports · doi:10.1007/s40124-021-00248-7 · Cited by 6
Amadou, C., Melki, V., Allain, J., Clavel, S., Gouet, D., Chaillous, L., Catargi, B., Schaeplynck-Belicard, P., Petit, C., Thivolet, C. H., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289684 · Cited by 5
Ernst, G., Kim-Dorner, S.-J., Hampel, M., Fritsch, H., & Lange, K. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005243 · Cited by 5
Michaels, V. R., Crocket, H. R., Boucsein, A., Zhou, Y., Paul, R. G., Wiltshire, E. J., Jefferies, C., de Bock, M. I., & Wheeler, B. J. (2025) · Diabetic Medicine · doi:10.1111/dme.70197 · Cited by 5
“17,18 This is concerning as ignored alarms can lead to missing hyperglycaemic and hypoglycaemic episodes.”
Chowdhury, S., Sarkar, S., Das, A., Kar, K., & Chakraborty, P. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100027 · Cited by 8
Pei, Y., Ke, W., Lü, J., Lin, Y., Zhang, Z., Peng, Y., Bi, Y., Li, Y., Hou, J., Zhang, X., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0234 · Cited by 5
Wong, J. Y., Styles, S. E., Wiltshire, E. J., de Bock, M. I., Boucsein, A., Palmer, O. J., & Wheeler, B. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15449 · Cited by 5
“7,9 A range of behavioural changes and self-management habits emerged among youth using AHCL.”
Vijayanand, S., Stevenson, P. G., Broad, E., Davis, E. A., Taplin, C. E., Jones, T. W., & Abraham, M. B. (2022) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16043 · Cited by 5
Yafi, M., Shah, A., & Vélez, K. (2023) · Translational Pediatrics · doi:10.21037/tp-23-145 · Cited by 5
Gómez, A. M., Henao, D. C., Parra, D., Kerguelen, A., Jaramillo, P., Gómez, Y., Múñoz, Ó., & Rondón, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02051-w · Cited by 5
Renard, É. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820901612 · Cited by 5
Wu, Z., Talbo, M. K., Lebbar, M., Messier, V., Courchesne, A., Brazeau, A., & RABASA-LHORET, R. P. R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111006 · Cited by 5
Generalized reinforcement learning control algorithm for fully automated insulin delivery system
Rachim, V. P., Yoo, J., Lee, J., Lee, Y., & Park, S. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.126909 · Cited by 5
Allogeneic Islet Transplantation: Chronicle of a Death Foretold?
Berney, T., Thaunat, O., & Berishvili, E. (2025) · Transplant International · doi:10.3389/ti.2025.14598 · Cited by 4
“Acceptability of AHCL is not universal (sensor issues, sports, . . . ) and in some cohorts, the percentage of dropout from AHCLs was up to 30% [33].”
Pilot Study of Early Adoption of Automated Insulin Delivery in Underresourced Youth
Yen, K., Belapurkar, S., Puckett, C., Chen, N. S., YGLECIAS, L., Bal, K., Hickey, J., CARELLI, L. L., LOUCEL, C. M., Lodish, M. B., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6886806 · Cited by 5
Empfehlungen zur Diabetes-Behandlung mit automatischen Insulin-Dosierungssystemen
Berge, T. V. D., Biester, S., Biester, T., Buchmann, A.-K., Datz, N., Grosser, U., Kapitzke, K., Klusmeier, B., Remus, K., Reschke, F., et al. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1652-9011 · Cited by 5
Trends in Time in Range–Related Publications and Clinical Trials: A Bibliometric Review
Patel, P. M., Abaniel, R. M., Dogra, N., Lo, C. B., Frazzitta, M. A., & Virdi, N. S. (2023) · Diabetes Spectrum · doi:10.2337/ds22-0085 · Cited by 4
Kogai, T., Sato, J., Yasuda, H., Ayame, T., Ozaki, A., Takagi, E., Koshibu, M., Nishida, Y., Ikeda, F., & Watada, H. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14350 · Cited by 7
Practical Diabetes Technology: Overcoming Barriers in the Real World
Messer, L. H., & WEINZIMER, S. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2511 · Cited by 4
Hybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes
Service, C. H. T. A. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.50 · Cited by 4
Recent advances in self-regulated drug delivery devices
Wang, Y., Chen‐Mayfield, T., Li, Z., & Hu, Q. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89925-3.00012-5 · Cited by 4
Overview of Currently Available Insulin Delivery Systems
Fried, H. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-75352-7_2 · Cited by 4
Julla, J., Amouyal, C., Lablanche, S., Sola‐Gazagnes, A., Joubert, M., Hadjadj, S., Signor, C. B., Bismuth, É., Chartier, Y., Garrec, N., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261465478 · Cited by 3
Jacobsen, S. S., Hommel, E. E., Ranjan, A. G., & Nørgaard, K. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0532 · Cited by 3
Aleppo, G., Bode, B. W., & Carlson, A. L. (2022) · Clinical Diabetes · doi:10.2337/cd21-0056 · Cited by 3
“a significant correlation between improved A1C and use of the system’s automatic insulin delivery mode (31).”
BackgroundNew technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Fuchigami, A., Kojimahara, Y., Yoshikawa, F., Higa, M., Ichijyo, T., Ikehara, K., Uchino, H., & Hirose, T. (2024) · Diabetology International · doi:10.1007/s13340-024-00778-7 · Cited by 2
“Even among those continuing auto mode, average utilization fell over time [24].”
Franceschi, R., Pertile, R., Marigliano, M., Mozzillo, E., Maffeis, C., Zaffani, S., Dusini, C., Antonelli, A., Maltoni, G., Candia, F. D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111962 · Cited by 2
Diabetes Without Math as Automation Advances: A Shifting Clinical Paradigm
Mora, P. A., Cook, K. P., & MacLeod, J. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0033 · Cited by 3
Manjelievskaia, J., Shah, V. N., Carlson, A. L., Isaacs, D. M., Wang, S. M., Pinsker, J. E., Messer, L. H., McDermott, K. W., Lavelle, K., Wall, S., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70147 · Cited by 3
Akiyama, T., Orime, K., Akamatsu, R., Suezono, T., Akiyama, M., Matsuura, A., Kaneko, A., Yamakawa, T., Shinoda, S., & Terauchi, Y. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70198 · Cited by 2
“Lal et al . reported that after 1 year of using the MiniMed TM 670G (cid:2) system, 62% of individuals who discontinued its use cited sensor-related issues, such as frequent calibration requirements and frequent alarms 21 .”
Closed-loop insulin delivery system enhances type 1 diabetes glycemic control
Fuchs, J., & Hovorka, R. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.050 · Cited by 2
La terapia con microinfusore: stato dell’arte
Bruttomesso, D. (2022) · il Diabete · doi:10.30682/ildia2201g · Cited by 3
Concept for the testing of automated functions in therapeutic medical devices
Henn, S., Kabuth, B., Schollemann, F., Hennigs, C., Männel, G., Angern, M., & Rostalski, P. (2022) · at - Automatisierungstechnik · doi:10.1515/auto-2022-0010 · Cited by 2
Ghaur, S. Y., Grinderslev, P. B., Leth‐Møller, M., Ovesen, P., Fuglsang, J., Fisker, S., McIntyre, D. H., & Kampmann, U. (2024) · Reproductive Medicine · doi:10.3390/reprodmed5010002 · Cited by 2
“In non-pregnant populations, closed-loop systems have been suggested to improve glycemic regulation compared with sensor-augmented insulin pumps [23,24].”
BackgroundHealth-Care Utilization and Outcomes in Young Adults With Type 1 and Type 2 Diabetes
Zenno, A., Huang, A., Roberts, A. J. C., & Pihoker, C. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae115 · Cited by 2
Update Typ-1-Diabetes bei Kids: Insuline, Technologie, Telemedizin
Kapellen, T. M. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3755-4 · Cited by 2
“So zog die notwendige Kalibrierung bei ersten zugelassenen System bei Jugendlichen und Erwachsenen teilweise eine Kalibriermüdigkeit nach sich, die dazu führte, dass bei einem Teil der Patienten das System nicht mehr im automatisierten Modus verwendet wurde [21].”
BackgroundSchoelwer, M. J., Bisio, A., Breton, M. D., & DeBoer, M. D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0405 · Cited by 1
Sepsis prediction model derived from hospital-arrival clinical data
Balamuth, F. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.051 · Cited by 1
Kovatchev, B. P., & Breton, M. D. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0209 · Cited by 1
L'insulinothérapie au xxie siècle : une symphonie de plus en plus harmonieuse
Benhamou, P., Hanaire, H. P., & Renard, É. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00179-6 · Cited by 1
#We don't have to wait any more Closed-loop systems: transforming the landscape
Boughton, C. K., & Hovorka, R. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.374 · Cited by 1
Hybrides AID-System im Alltags-Check
Thomas, A. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4568-4 · Cited by 1
Metadata
- Authors
- Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Lal, Rayhan A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-23
- Volume
- 42
- Issue
- 12
- Pages
- 2190-2196
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6868462
- OpenAlex
- W2976192468
- Cited by
- 215
- References
- 29
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 25 · 2023: 35 · 2022: 36 · 2021: 62 · 2020: 33 · 2019: 4
- FWCI
- 27.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1-TR-001085, P30-DK-116074, 1K12-DK-122550)
- National Institute for Diabetes and Digestive and Kidney Diseases (T32-DK-007217, 1K12-DK-122550)
- NIH (DP3-DK-104059, DP3-DK-101055, DK-14024)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- hybrid closed-loop system, type 1 diabetes, continuous glucose monitoring, device utilization, hypoglycemia, sensor calibration, glycemic control, HbA1c, usability, human factors, time in range
- MeSH terms
- Adolescent, Adult, Blood Glucose, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Prospective Studies, United States, Blood Glucose Self-Monitoring, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.